

Simon Pacey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11219877/publications.pdf>

Version: 2024-02-01

21
papers

4,241
citations

516710

16
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

7818
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. <i>Genome Research</i> , 2022, 32, 215-227.	5.5	41
2	Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100093.	1.1	14
3	A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 2708-2716.	7.0	49
4	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	670
5	A novel <i>Atg5</i> -shRNA mouse model enables temporal control of Autophagy <i>in vivo</i> . <i>Autophagy</i> , 2018, 14, 1256-1266.	9.1	35
6	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017, 17, 223-238.	28.4	1,786
7	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, 1778-1785.	1.6	96
8	Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8553-8553.	1.6	7
9	Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. <i>Oncotarget</i> , 2016, 7, 24111-24124.	1.8	16
10	18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11567-11567.	1.6	0
11	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2015, 16, e447-e459.	10.7	325
12	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> “ <i>RAF</i> Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 4251-4261.	7.0	60
13	A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , 2012, 30, 341-349.	2.6	122
14	Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. <i>Investigational New Drugs</i> , 2011, 29, 481-488.	2.6	46
15	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 1561-1570.	7.0	178
16	Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin. <i>Clinical Cancer Research</i> , 2010, 16, 3795-3804.	7.0	57
17	Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells. <i>Cancer Research</i> , 2009, 69, 1966-1975.	0.9	107
18	Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 6663-6673.	7.0	115

#	ARTICLE	IF	CITATIONS
19	Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. <i>Biomarkers in Medicine</i> , 2007, 1, 399-417.	1.4	29
20	Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 2845-2850.	1.5	9
21	Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 4152-4161.	1.6	479